N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide
| Title | Journal |
|---|---|
| From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells. | Toxicological sciences : an official journal of the Society of Toxicology 20170601 |
| Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. | Reproductive toxicology (Elmsford, N.Y.) 20150815 |
| Pathways in pulmonary arterial hypertension: the future is here. | European respiratory review : an official journal of the European Respiratory Society 20121201 |
| Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. | Life sciences 20121015 |
| The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. | Journal of medicinal chemistry 20120913 |
| Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. | The AAPS journal 20120301 |
| Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. | PloS one 20120101 |
| Macitentan: entry-into-humans study with a new endothelin receptor antagonist. | European journal of clinical pharmacology 20111001 |
| Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. | Neoplasia (New York, N.Y.) 20110201 |
| Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. | Current opinion in investigational drugs (London, England : 2000) 20100901 |
| Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091105 |
| Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. | The Journal of pharmacology and experimental therapeutics 20081201 |